loader
Please Wait
Applying Filters...
menu
    • menu

    List of Written Confirmation(s) issued for Imatinib Mesilate Active Pharmaceutical Ingredient (API)

    Client Email Product
    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Aug 2024: Otsuka buys Jnana, Lilly’s market cap gains by over US$ 108 bn post new guidance

    Stock Recap
    #PipelineProspector

    Menu

    Imatinib Mesilate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 959Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    27/12/2021 Cdymax
    India
    		 M/s Cdymax WC-0327n Imatinib Mesilate IH 2021-09-01 2024-07-15 Plot No 116/117, KIADB Industrial Area, Jigani, Bangalore,Karnataka, India
    29/04/2020 Cipla
    India
    		 M/s. Cipla Limited,  WC-0113 Imatinib Mesylate Alpha Form /beta Form(IH) 2022-06-20 2025-08-08 Virgonnagar, Old Madras Road, Bangalore-560 049